LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced the commercial launch of The Monarch eTNS System at the annual meeting of ...
Trial to be conducted at UCLA and funded by a grant from National Institute on Alcohol Abuse and Alcoholism (NIAAA) First phase of trial will enroll up to 30 children ages 8 – 12 with exposure to ...
Please provide your email address to receive an email when new articles are posted on . The FDA cleared the use of NeuroSigma’s second-generation Monarch eTNS System for treating pediatric ADHD. The ...
LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating ...
For decades, managing ADHD has meant getting a prescription for Adderall or Ritalin. Now children have another option: the Monarch external Trigeminal Nerve Stimulation (eTNS) system, an ADHD ...
Neurosigma Inc. has received FDA breakthrough device designation for its Monarch ETNS system to treat drug-resistant epilepsy (DRE). The neuromodulation therapy uses noninvasive external trigeminal ...
FOSTER CITY, CA—Feb. 15, 2012— EFI, a world leader in customer-focused digital printing innovation, announced that Bloomington Process Offset, known as bopi, has recently installed the EFI Monarch MIS ...
Johnson & Johnson released new studies this month examining the efficacy of robotic-assisted bronchoscopy (RAB) delivered through its Monarch platform. The research, presented at the American College ...
A revolutionary processor package that changes its architecture to adapt to the demands of different computing tasks more than met design expectations in recent trials. Near-term applications for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback